biotech / news / / CNBC TV18
A Bloomberg report indicated that the Trump administration is planning tariffs on pharmaceutical companies that have not entered into agreements to ensure lower drug prices in the US.
The Trump administration is considering tariffs up to 100% on imported branded and patented medicines.
KEY POINTS
- Companies with US drug pricing agreements or participation in TrumpRx.gov have avoided proposed tariffs.
- Sun Pharma faces heightened risk due to its significant US branded drug exposure and lack of agreement.
- Pfizer, AstraZeneca, Roche, Novartis, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, and GSK have secured tariff waivers through agreements.
COMPANIES
Summarized by Newsio from CNBC TV18. How we summarize →